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Abstract
Background: Thrombectomy for the treatment of ST elevation myocardial infarction (STEMI) is a simple and
intuitive idea. In the 2000s, several studies evaluated the efficacy of thrombus aspiration and showed that thrombus
aspiration led to improved myocardial perfusion, as assessed by a range of surrogate endpoints. These findings
were confirmed by meta-analyses. However, the favorable results with thrombo-aspiration in STEMI were
subsequently called into question by data indicating not only a lack of efficacy, but a risk of potentially deleterious
complications.
Discussion: We review here the scientific evidence in favor of, then subsequently against the utility of
thrombo-aspiration in the setting of STEMI, and examine how such discordant findings come to be observed, e.g.
technical problems, faulty study design, weak statistical power, or a true lack of efficacy of thrombus aspiration. We
also consider what these conflicting results may mean for the future of this technique in the treatment of ST
elevation myocardial infarction.
Summary: Over the course of its development, significant evidence has cumulated both in favour of, and against
thrombectomy for the treatment of ST elevation myocardial infarction. Overall, although its place among the
therapeutic armamentarium for ST elevation myocardial infarction is now limited, it is likely that it will continue to
be used to treat specific cases, after careful consideration of the limited success of our catheters at retrieving
effective thrombus, the risk of stroke linked to the procedure, and the special attention that needs to be paid to
avoid a risk of embolization during removal of thrombotic material.
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Background
Thrombectomy for the treatment of ST elevation myo-
cardial infarction is a simple and intuitive idea. It doesn’t
take much convincing that removing part or all of the
thrombus that is blocking the artery before implanting a
stent is beneficial, both in terms of the obstruction, and
at the level of the microcirculation. The scientific evi-
dence in support of this concept is based on several pub-
lications. Between 2002 and 2005, seven small-sized
studies reported favorable results with thrombectomy,
and four of these showed a significant difference in
terms of arterial patency. A subsequent meta-analysis
confirmed that thrombectomy prior to angioplasty im-
proved coronary reperfusion [1]. Lastly, the TAPAS
study [2], published in 2008 and including 1071 patients
with STEMI, evaluated the efficacy of thrombus aspir-
ation in terms of a surrogate criterion, namely myocar-
dial blush grade. The results met the expectations of the
cardiology community, showing that the thrombus aspir-
ation group had better myocardial perfusion, regardless
of whether assessed in terms of blush grade, ST reso-
lution, or ST elevation persistence on the ECG. The clin-
ical impact of these findings was reported 1 year later,
with a spectacular 43 % reduction in all-cause mortality
in the thrombus aspiration group [3]. Indeed, the edi-
torialist in The Lancet heralded a victory over the no-
reflow phenomenon [4], and – even though the reduc-
tion in mortality seems hardly credible in a study of
1000 STEMI patients – subsequent guidelines gave a
grade IIA recommendation for routine thrombus aspir-
ation [5].
* Correspondence: Fiona.ecarnot@univ-fcomte.fr
EA3920, Department of Cardiology, University Hospital Jean Minjoz, 3
Boulevard Fleming, 25000 Besançon, France
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Schiele and Ecarnot BMC Cardiovascular Disorders  (2016) 16:97 
DOI 10.1186/s12872-016-0291-6
Efficacy and safety called into question
The earliest studies did not address the technical diffi-
culties of manual thrombus aspiration. There was no
mention of complications; effective thrombus retrieval
was achieved in most cases, and there were few proced-
ural failures. The magnitude of the reduction in mortal-
ity reported in the Thrombus Aspiration during primary
percutaneous coronary intervention in Acute myocardial
infarction Study(TAPAS) study also raised some eye-
brows. Is it really possible to achieve such a gain? By
way of comparison, the advent of stenting during bal-
loon angioplasty did not lead to a reduction in mortality,
and usually, studies with a sample size 10 times as large
are required to show a reduction in mortality in STEMI.
Two large, randomized studies ensued, aiming to evalu-
ate clinical criteria, each including almost 10,000 pa-
tients, a randomized study associated with a registry
study namely Thrombus Aspiration in ST elevation
Myocardial Infarction in Scandinavia (TASTE) [6] and a
large-scale international trial Thrombectomy with PCI
versus PCI Alone in Patients with STEMI (TOTAL) [7].
The results in terms of myocardial reperfusion were less
salient than in the TAPAS study, although they did tend
in the same direction, and thrombectomy was shown to
reduce distal emboli. However, the results in terms of
clinical criteria were less encouraging, namely there was
no benefit on mortality at 1 year in either study. As if
the lack of benefit wasn’t disappointing enough, the very
safety of thrombus aspiration was also called into ques-
tion. A second meta-analysis of thrombus aspiration
published in 2013 [8] reported a trend towards a higher
risk of stroke with this technique. Furthermore, similar
findings were reported in the 1-year follow-up of the
TOTAL study, where a significant increase in the risk of
stroke with thrombectomy was observed [9]. The ac-
companying editorial in the New England Journal of
Medicine suggested “that the time has arrived to prepare
a requiem for routine manual thrombectomy” [10], and
again, subsequent guidelines took into account the new
evidence, and lowered the level of recommendation for
thrombus aspiration from IIA to IIB [11].
Discussion
The fact that successive randomized studies produced
disparate results is not unusual in cardiology, or in
any field, for that matter. Naturally, the largest and
most recent studies are the ones that stay foremost in
the collective memory. The findings of TASTE and
TOTAL strongly prompt the cardiological community
to abandon the practice of thrombus aspiration once
and for all, since it incurs a higher risk, for no clin-
ical benefit. However, things are not always that
simple in reality. We may recall that in 2006, for ex-
ample, active stents were also called into serious
doubt. So before we put the last nail in thrombect-
omy’s coffin, maybe a frank discussion of the efficacy
and safety is warranted.
The risk of stroke seems to be the main adverse event
associated with thrombus aspiration, and was brought to
light most prominently in the TOTAL study. The pro-
posed mechanism of stroke in this context is cerebral
embolization of the thrombotic material extracted. This
is a plausible theory, and if such were the case, it is con-
ceivable that improvements in either the technique or
the equipment, and the exercise of particular caution,
could circumvent this risk. There is also the possibility
of a difference in the risk of stroke occurring purely by
chance. Indeed, the actual number of strokes was quite
small. In the meta-analysis published in 2013, the actual
difference in stroke between thrombus aspiration and
PCI was 4 patients (13/1054 vs 17/1057) [8], and was 24
patients (60/5035 vs 36/5029) in the TOTAL study [7].
Additionally, the stroke may have been caused by other
factors, not related to the procedure, as suggested by the
fact that many of the strokes occurred more than 30 days
after angioplasty.
Is the lack of efficacy related to technical problems?
The results of thrombus aspiration observed in coronary
artery disease are in stark contrast with the findings of 5
randomized studies in the context of stroke, all pub-
lished in 2015 [12–16]. Why is thrombus extraction suc-
cessful in stroke but not in STEMI? Given the vast
experience of cardiologists in angioplasty procedures,
and the large number of thrombectomy systems already
tested in clinical practice, it is hard to believe that this
problem could stem from poorly trained operators, or
poorly designed endocoronary systems. It is more likely
that cerebral thrombus, often of embolic origin, is easier
to capture and retrieve than platelet-rich thrombus
forming locally on an atherothrombotic plaque, as found
in STEMI.
Or is the study design at fault? There are many exam-
ples of cases where the design of a study, the selection
of patients, or the choice of endpoints had a major im-
pact on the results. The fact that the efficacy of
thrombus aspiration found in small trials could not be
replicated in TASTE or TOTAL is not unexpected. Evi-
dently, a reduction in mortality such as that observed
in the TAPAS trial generates many hypotheses, but does
not prove anything. However, doubts persist because of
the non-selection of patients in these trials. In particu-
lar, TASTE and TOTAL investigated a strategy of sys-
tematic thrombus retrieval with randomization taking
place before angiography, and thus, before it was
known whether the quantity of thrombus justified
thrombus retrieval or not. In routine practice, the oper-
ator decides to perform thrombus aspiration based on
the size of the artery, the accessibility of the lesion, and
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the quantity of thrombus estimated by angiography.
This important question will no doubt remain un-
answered, since, in the TOTAL study, the artery was
occluded in 65 % of cases, and per the study design,
bailout thrombectomy was allowed if the initial PCI
alone strategy failed, namely in case of persisting large
thrombus after stent deployment [17]. Indeed, bailout
thrombectomy was performed in 355 patients (7.1 %) of
the PCI-alone group, and an additional 69 patients
(1.4 %) crossed over from the PCI-alone to the thromb-
ectomy group. Finally, subgroup analysis from TASTE
and TOTAL does not help to identify the best candi-
dates for thrombectomy, since the only significant
interaction in the TASTE study concerned the efficacy
of thrombus retrieval in women, and results seemed to
be better in high-volume centres. In the TOTAL study,
comparison of pre-specific subgroups according to
TIMI thrombus grade (<3 vs ≥3, and <4 vs ≥4) did not
show any significant difference in terms of the primary
endpoint.
Some other design differences between the TOTAL
and TASTE trials also deserve to be highlighted. Firstly,
the data in TASTE come from a well-established Scandi-
navian multicenter registry, and therefore, the general
population of which this group is representative may
have a different mortality profile compared to the popu-
lation represented by the sample in the TOTAL trial.
Secondly, in TOTAL, events were adjudicated independ-
ently, whereas data were monitored as part of the usual
registry validation in TASTE. Third, in the TOTAL trial,
74 % of patients had a thrombus grade 4–5, compared
to only 32 % in TASTE. These discrepancies, amongst
others, may contribute to the conflicting results ob-
served in this area.
What about the endpoint ? It is hard to question the
validity of all-cause mortality as an endpoint, as used in
the TASTE study, although in the TOTAL trial, the
primary endpoint was a composite of cardiovascular
death, recurrent MI, cardiogenic shock, or new or
worsening NYHA class IV heart failure occurring
within 180 days. In the report of the 1-year follow-up
from the TOTAL study [9], a meta-analysis is presented
including all studies of this technique, with a pooled
population of over 20,000 patients. The excess risk of
stroke is statistically significant, but with relatively few
events (85/9773 vs 59/9813, i.e. a difference of 27
strokes for 19,586 patients evaluated). Conversely, the
difference in mortality is statistically non-significant
(OR 0.90, 95 % CI 0.79–1.02), but numerically in favour
of thrombus aspiration (452/10250 vs 503/10282). Thus,
thrombus aspiration saves two lives, at the cost of incur-
ring one stroke. It is regrettable that there was no com-
parison of the net clinical benefit in a population of
selected patients after coronary angiography.
Conclusions
So is there still room for thrombectomy? The interven-
tional cardiologist would probably find it hard to say
that there is no longer any room for thrombectomy, but
it has to be acknowledged that its place is now consider-
ably limited. Nonetheless, the principle of improving
myocardial reperfusion is not called into question and it
would be advisable to keep a few thrombus retrieval
catheters in the stockroom for special cases. The indica-
tions need to be discussed, taking into account the limited
success of our catheters at retrieving effective thrombus,
the risk of stroke linked to the procedure, and the special
attention that needs to be paid to avoid a risk of
embolization during removal of thrombotic material.
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